Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. (Q41516241)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

review article

1 reference

title

Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

E Domingo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

L Menéndez-Arias

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

M E Quiñones-Mateu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

A Holguín

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

M Gutiérrez-Rivas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

J Quer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

I S Novella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

J J Holland

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 January 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

99-128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

env gene sequences of primary HIV type 1 isolates of subtypes B, C, D, E, and F obtained from the World Health Organization Network for HIV Isolation and Characterization

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Point mutant frequencies in the pol gene of human immunodeficiency virus type 1 are two- to threefold lower than those of env.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Rapid viral quasispecies evolution: implications for vaccine and drug strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Resistance, drug failure, and disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

RNA virus mutations and fitness for survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Replication infidelity during a single cycle of Ty1 retrotransposition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Error-prone retrotransposition: rime of the ancient mutators

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

RNA virus populations as quasispecies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Rates of spontaneous mutation among RNA viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Nucleotide sequence heterogeneity of an RNA phage population.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

The origin of genetic information: viruses as models

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

On the nature of virus quasispecies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Exponential increases of RNA virus fitness during large population transmissions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Antigenically profound amino acid substitutions occur during large population passages of foot-and-mouth disease virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Viral dynamics in human immunodeficiency virus type 1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Fitness of RNA virus decreased by Muller's ratchet

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Rapid fitness losses in mammalian RNA virus clones due to Muller's ratchet

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Genetic lesions associated with Muller's ratchet in an RNA virus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

THE RELATION OF RECOMBINATION TO MUTATIONAL ADVANCE

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

The red queen reigns in the kingdom of RNA viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Basic concepts in RNA virus evolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Reproducible nonlinear population dynamics and critical points during replicative competitions of RNA virus quasispecies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Hepatitis B variant in Europe

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Vaccine-induced escape mutant of hepatitis B virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Viral genetic variation: hepatitis B virus as a clinical example

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Hepatitis B virus surface mutations associated with infection after liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Vaccination of chimpanzees against infection by the hepatitis C virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

HIV vaccines: where we are and where we are going

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

A perspective on AIDS vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Frequency of diminazene-resistant trypanosomes in populations of Trypanosoma congolense arising in infected animals following treatment with diminazene aceturate

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Molecular biology and evolution of resistance of toxicants

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Molecular pathogenesis of liver disease during persistent hepatitis B virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Genomic variations in the hepatitis B core gene: a possible factor influencing response to interferon alfa treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Zidovudine: five years later

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Isolation and characterization of a dideoxyguanosine triphosphate-resistant mutant of human immunodeficiency virus reverse transcriptase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Human immunodeficiency virus reverse transcriptase. Functional mutants obtained by random mutagenesis coupled with genetic selection in Escherichia coli

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Nucleoside-analogue resistance involves the p66 subunit of HIV-1 RT

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives)

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Sensitivity of (138 Glu-->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Site-directed mutagenesis of arginine 72 of HIV-1 reverse transcriptase. Catalytic role and inhibitor sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Structure-based inhibitors of HIV-1 protease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

31 March 2020

The not-so-great escape

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8861-5_4

10.1007/978-3-0348-8861-5_4

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9204684%20AND%20SRC:MED&resulttype=core&format=json